MedTrace Logo

Comparison of Two Endoscopic Biopsic Needles for Pancreatic Tumors

NCT03444051 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2018-02-23

No results posted yet for this study

Summary

This observational study compared quality of histological sampling of pancreatic EUS-FNB with the 20-gauge Procore® and 22-gauge Acquire® needles. In total, 68 patients were recruited. Histological diagnosis was achieved and a histological core biopsy was obtained in 82% of patients (28/34) in the 20-gauge Procore® group and 97% of patients (33/34) in the 22-gauge Acquire® group (P=0.1). Core biopsy specimens obtained were significantly longer with the 22-gauge Acquire® needle with a mean cumulative length of tissue core biopsies per needle pass of 4,33±3,46mm vs. 7,9±4,35mm for the 20-gauge Procore® (P\<0,01). Reproducibility of this simple histological criterion was validated in intra and inter-observer.

Conditions

  • Pancreatic Tumor
  • Puncture

Interventions

PROCEDURE

EUS-FNB with 20-gauge Procore® needle

Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 20-gauge Procore® needle

PROCEDURE

EUS-FNB with 22-gauge Acquire® needle

Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 22-gauge Acquire®

Sponsors & Collaborators

  • Société Française d'Endoscopie Digestive

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2017-12-01
Completion
2017-12-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03444051 on ClinicalTrials.gov